Image Sourced ShutterStock
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • HeraMED secures MOU to conduct the pilot trial and launch medical-grade foetal heart rate monitor in Mexico
  • HeraMED secured the pilot trial ahead of the potential launch with plans of the monitors to be distributed by IBL across 48 MacStores

HeraMED has secured an agreement with IBL to progress a pilot trial and to sell HeraBEAT foetal heart rate monitors in Mexico.

HeraMED Limited is an innovative medical technology company which provides smart pregnancy monitoring solutions. HeraMED plans to do this is by commercialising the HeraBEAT device, which is an advanced, medical-grade ultrasound monitoring device.

The Company has received an initial purchase order for the HeraBEAT Monitor valued at US$35,000. IBL will use its Mexican partner, MacStore to distribute the monitor throughout Mexico.

MacStore holds distribution rights for Apple products in Mexico which sells those products through its 48 MacStore outlets across the country. As part of the agreement IBL will supply the HeartBEAT Monitors to designated MacStores and promote the device and feature it on its Ecommerce site.

IBL will be responsible for the approval, costs and registration of the HeraBEAT Monitors by any regulatory and health authorities in Mexico. IBL will need to ensure that MacStore promotes the device through its network of hospitals, insurance and medical professionals in Mexico.

“We have partnered with IBL Holding and one of Mexico’s leading retail groups to progress a pilot trial, which once completed is expected to derisk considerably a full-scale roll out of HeraBEAT Monitors in Mexico,” HeraMED CEO and Co-founder, David Groberman said.

“HeraMED looks forward to updating its shareholders on product uptake and feedback from consumers and medical professionals in Mexico in the coming months,” he said.

HeraMED will initially be able to conduct market research and ensure any functionality issues from a device and smartphone app standpoint are addressed and free of issues, before a full scale launch takes place.

HMD by the numbers
More From The Market Herald

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase…

Little Green Pharma positions itself for growth in France’s emerging medicinal cannabis market

Little Green Pharma (ASX:LGP) is primed for substantial growth after a major amendment to the French…

PolyNovo posts $8m sales month and $9m revenue month for November

Disruptive medical device company PolyNovo (ASX:PNV) has announced record monthly sales of $8.8 million for November…
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong

Imugene set to secure European patent for cancer vaccine; announces new phase II CRC cancer trial in 2024

Imugene (ASX:IMU) is on the verge of securing approval from the European Patent Office (EPO) for…